The BBB penetrating drugs market is projected to grow at an annualized rate of ~154%, till 2030::>
To order this 400+ page report, which features 145+ figures and 205+ tables, please visit this https://www.rootsanalysis.com/reports/310/request-sample.html
Key Market Insights
- More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treatment of CNS disorders; there are 35+ technology platforms for the development of BBB penetrant drugs
- Majority of drug candidates are currently in the early stages of development, and are intended for the treatment of neurological conditions; a large proportion of the existing pipeline molecules are biologics
- In order to achieve a competitive edge, several technology developers are presently focusing on the integration of advanced technical features into their proprietary drug development / delivery platforms
- An assessment of 240+ drug developers, focused on Parkinson’s and Alzheimer’s diseases, revealed that many such firms are likely to partner with technology providers in order to leverage their BBB penetration expertise
- Over the years, more than 16,700 patents related to BBB technologies have been filed / granted to various industry and non-industry players, indicating the pace of R&D activity in this burgeoning field of research
- Foreseeing a lucrative future, several private and public investors have invested close to USD 1 billion, across more than 70 funding instances
- Revenues generated from the sales of BBB penetrating drugs are anticipated to be well distributed across different types of molecules, target disease indications and various global regions over time
- In the near-term, the opportunity is likely to be driven by licensing activity driven by the capability of leading BBB penetrating technologies to successfully facilitate drug delivery into the brain
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Structure of the Human Brain
3.3. Global Burden on Neurological Disorders and Impact of Coronavirus Disease (COVID-19)
3.4. Strategies for Drug Delivery to the Central Nervous System (CNS)
3.4.1. Invasive Techniques
3.4.1.1. Systemic Administration of Therapeutics
3.4.1.2. Direct Administration of Therapeutics
3.4.1.3. Intracerebral Devices and Implants
3.4.2. Non-Invasive Techniques / Approaches
3.4.2.1. Liposomes
3.4.2.2. Exosomes
3.4.2.3. Prodrugs
3.4.2.4. Nanoparticles and Microspheres
3.4.2.5. Novel Formulations and Conjugates
3.4.3. Chemical Delivery Systems
3.5. Blood-Brain Barrier (BBB)
3.5.1. Key Historical Milestones
3.5.2. Structure and Key Components
3.5.3. Key Functions
3.6. Strategies for Drug Delivery across the BBB
3.6.1. Increasing Permeability by Temporary Disruption of the BBB
3.6.2. Pharmacological Strategies to Facilitate Transport Across the BBB
3.7. Challenges Associated with BBB Penetration and CNS Drug Delivery
3.8. Prevalent Trends Related to Non-Invasive BBB Penetration Technologies
3.8.1. Emerging Focus Areas
3.8.2. Key Historical Trends
3.8.3. Geographical Activity
3.9. Concluding Remarks
4. MARKET LANDSCAPE: NON-INVASIVE BBB PENETRATION
4.1. Chapter Overview
4.2. Non-Invasive BBB Penetration Technologies: Overall Market Landscape
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Underlying Principle
4.2.3. Analysis by Compatible Pharmacological Molecule(s)
4.2.4. Analysis by Target Receptor(s)
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Patent Availability
4.2.7. Analysis by Licensing Activity
4.3. Non-Invasive BBB Penetration Technology Providers: Overall Market Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
5. MARKET LANDSCAPE: BBB PENETRATING DRUGS
5.1. Chapter Overview
5.2. BBB Penetrating Drugs: Development Pipeline
5.2.1. Analysis by Phase of Development
5.2.2. Analysis by Type of Molecule
5.2.3. Analysis by Affiliated BBB Penetration Technology
5.2.4. Analysis by Route of Administration
5.2.5. Analysis by Target Disease Indication(s)
5.2.6. Analysis by Therapeutic Area(s)
5.3. BBB Penetrating Drugs: Additional Information
5.4. BBB Penetrating Drug Developers: Overall Market Landscape
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size
5.4.3. Analysis by Location of Headquarters
5.4.4. Leading Drug Developers: Analysis by Number of Drugs
5.4.5. Leading Drug Developers: 4D Bubble Analysis based on Pipeline Strength, Target Disease Indication and Company Size
5.4.6. Heptagon Representation: Analysis by Phase of Development and Key Disease Indications
5.4.7. Tree Map Representation: Analysis by Key Disease Indications and Size of the Company
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Leading Players based in North America
6.2.1. Angiochem
6.2.1.1. Company Overview
6.2.1.2. Technology Overview
6.2.1.3. Product Portfolio
6.2.1.4. Recent Developments and Future Outlook
6.2.2. ArmaGen
6.2.2.1. Company Overview
6.2.2.2. Technology Overview
6.2.2.3. Product Portfolio
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Denali Therapeutics
6.2.3.1. Company Overview
6.2.3.2. Technology Overview
6.2.3.3. Product Portfolio
6.2.3.4. Recent Developments and Future Outlook
6.2.4. ICB International
6.2.4.1. Company Overview
6.2.4.2. Technology Overview
6.5.4.3. Product Portfolio
6.2.4.4. Recent Developments and Future Outlook
6.2.5. Lauren Sciences
6.2.5.1. Company Overview
6.2.5.2. Technology Overview
6.2.5.3. Product Portfolio
6.2.5.4. Recent Developments and Future Outlook
6.3. Leading Players based in Europe
6.3.1. BioArctic
6.3.1.1. Company Overview
6.3.1.2. Technology Overview
6.3.1.3. Product Portfolio
6.3.1.4. Recent Developments and Future Outlook
6.3.2. Cyclenium Pharma
6.3.2.1. Company Overview
6.3.2.2. Technology Overview
6.3.2.3. Product Portfolio
6.3.2.4. Recent Developments and Future Outlook
6.3.3. Iproteos
6.3.3.1. Company Overview
6.3.3.2. Technology Overview
6.3.3.3. Product Portfolio
6.3.3.4. Recent Developments and Future Outlook
6.3.4. Medesis Pharma
6.3.4.1. Company Overview
6.3.4.2. Technology Overview
6.3.4.3. Product Portfolio
6.3.4.4. Recent Developments and Future Outlook
6.3.5. Ossianix
6.3.5.1. Company Overview
6.3.5.2. Technology Overview
6.3.5.3. Product Portfolio
6.3.5.4. Recent Developments and Future Outlook
6.3.6. Vect-Horus
6.3.6.1. Company Overview
6.3.6.2. Technology Overview
6.3.6.3. Product Portfolio
6.3.6.4. Recent Developments and Future Outlook
6.4. Leading Players based in Asia-Pacific
6.4.1. JCR Pharmaceuticals
6.4.1.1. Company Overview
6.4.1.2. Technology Overview
6.4.1.3. Product Portfolio
6.4.1.4. Recent Developments and Future Outlook
7. TECHNOLOGY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Methodology and Key Parameters
7.3. BBB Penetration Technologies: Platform Competitiveness Analysis
8. NON-INVASIVE BBB PENETRATION TECHNOLOGIES: POPULAR APPROACHES
8.1. Chapter overview
8.2. Receptor Mediated Transcytosis (RMT)
8.2.1. Type of Target Receptors
8.2.1.1. Diphtheria Toxin Receptor
8.2.1.2. Insulin Receptor and Insulin-like Growth Factor Receptor
8.2.1.3. Low Density Lipoprotein Receptor-Related Proteins (LRP-1 and LRP-2)
8.2.1.4. Transferrin Receptor
8.2.2. Types of RMT Approaches
8.2.2.1. Bispecific Antibody-based Approach
8.2.2.2. Molecular Trojan Horse-based Approach
8.2.2.2.1. Important Considerations for Designing Molecular Trojan Horses
8.2.2.2.2. Considerations for Designing a Trojan Horse Liposome (THL)
8.2.2.2.3. Popular Conjugation Strategies
8.2.2.2.3.1. Direct Coupling Approach
8.2.2.2.3.2. Nanoparticles-based Approach
8.3. Increasing the Permeability of the BBB
8.3.1. Use of Ultrasound Waves
8.3.2. Use of High-Frequency Electric Field
8.4. Passive Diffusion
8.5. Novel Approaches
8.5.1. Cell Penetrating Peptides
8.5.2. Macrocycles
8.5.3. Organ-on-a-Chip Technology
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Non-Invasive BBB Technologies and Drugs: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Focus Area
9.3.6. Analysis by Type of Molecule
9.3.7. Analysis by Target Disease Indication
9.3.8. Most Active Players: Analysis by Number of Partnerships
9.3.9. Most Popular Technologies: Analysis by Number of Partnerships
9.3.10. Regional Analysis
9.3.11. Intercontinental and Intracontinental Agreements
10. ANALYSIS OF RECENT LICENSING AGREEMENTS
10.1. Chapter Overview
10.2. Licensing Agreements: Definition and Importance in Pharmaceutical Industry
10.3. Types of Licensing Agreements
10.3.1. Out-Licensing Agreements
10.3.2. In-Licensing Agreements
10.4. Components of Licensing Agreements
10.5. Recent Examples of BBB-Related Technology Licensing Agreements
10.5.1. Analysis by Year of Agreement
10.5.2. Analysis by Type of Licensing Agreement
10.5.3. Analysis by Type of Owner
10.5.4. Most Active Players: Analysis by Number of Licensing Agreements
10.5.5. Most Popular Technologies: Analysis by Number of Licensing Agreements
10.5.6. Regional Analysis
10.5.7. Intercontinental and Intracontinental Licensing Agreements
10.6. Case-in-Point: Technology Licensing Timeline
10.6.1. Sumitomo Dainippon Pharma and JCR Pharmaceuticals
10.6.2. Denali Therapeutics and Sanofi
10.6.3. biOasis Technologies and Prothena
10.6.4. Vect-Horus and Janssen Pharmaceuticals
10.7. Concluding Remarks
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Non-Invasive BBB Penetration Technologies and Drugs: List of Funding and Investments
11.3.1. Analysis by Number of Instances
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Analysis by Type of Company
11.3.5. Analysis by Purpose of Funding
11.3.6. Analysis by Type of Molecule
11.3.7. Analysis by Target Disease Indication
11.3.8. Analysis by Geography
11.3.9. Most Active Players: Analysis by Number of Funding Instances
11.3.10. Most Popular Technologies: Analysis by Number of Funding Instances
11.3.11. Most Active Investors: Analysis by Number of Funding Instances
11.4. Concluding Remarks
12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Non-Invasive BBB Penetration Technologies: Patent Analysis
12.3.1. Analysis by Application Year
12.3.1.1. Analysis by Filed Patent Applications
12.3.1.2. Analysis by Granted Patent Applications
12.3.2. Analysis by Issuing Authority / Patent Offices Involved
12.3.3. Analysis by CPC Symbols
12.3.4. Emerging Focus Areas
12.3.5. Analysis by Type of Organization
12.3.6. Leading Assignees: Analysis by Number of Patents
12.4. Non-Invasive BBB Technologies: Patent Valuation Analysis
13. DRUG DEVELOPMENT STRATEGY ANALYSIS
13.1. Chapter Overview
13.2 Scope and Methodology
13.3. Strategies Adopted by Late-Stage Drug Candidates
13.3.1. Drug A
13.3.2. Drug B
13.3.3. Drug C
13.3.4. Drug D
13.4. Concluding Remarks
14. MARKET POTENTIAL OF KEY NEUROLOGICAL DISORDERS
14.1. Chapter Overview
14.2. Market Potential of Key Neurological Disorders: 3D Bubble Chart Analysis
14.3. Key Neurological Disorders: Detailed Information
14.3.1. Alzheimer’s Disease
14.3.1.1. Disease Description
14.3.1.2. Epidemiology
14.3.1.3. Symptoms
14.3.1.4. Current Treatment Options
14.3.1.5. BBB Penetrating Drugs for Alzheimer’s Disease
14.3.1.6. Roots Analysis Perspective
14.3.2. Brain Cancer
14.3.2.1. Disease Description
14.3.2.2. Epidemiology
14.3.2.3. Symptoms
14.3.2.4. Current Treatment Options
14.3.2.4.1. Surgery
14.3.2.4.2. Radiation Therapy
14.3.2.4.3. Systemic Therapy
14.3.2.5. BBB Penetrating Drugs for Brain Cancer
14.3.2.6. Roots Analysis Perspective
14.3.3. Multiple Sclerosis
14.3.3.1. Disease Description
14.3.3.2. Epidemiology
14.3.3.3. Symptoms
14.3.3.4. Current Treatment Options
14.3.3.4.1. Treatment for Attacks
14.3.3.4.2. Treatments to Modify Progression
14.3.3.4.3. Interferons
14.3.3.5. BBB Penetrating Drugs for Multiple Sclerosis
14.3.3.6. Roots Analysis Perspective
14.3.4. Parkinson’s Disease
14.3.4.1. Disease Description
14.3.4.2. Epidemiology
14.3.4.3. Symptoms
14.3.4.4. Current Treatment Options
14.3.4.4.1. Pharmacological Management of Parkinson’s Disease
14.3.4.4.2. Non-Pharmacological Management of Parkinson’s Disease
14.3.4.4.3. Management of Parkinson’s Disease using Dietary Supplements
14.3.4.5. BBB Penetrating Drugs for Parkinson’s Disease
14.3.4.6. Roots Analysis Perspective
15. LIKELY PARTNER ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Potential Strategic Partners for Drug Development
15.3.1. Opportunities in North America
15.3.1.1. Most Likely Partners
15.3.1.2. Likely Partners
15.3.1.3. Less Likely Partners
15.3.2. Opportunities in Europe
15.3.2.1. Most Likely Partners
15.3.2.2. Likely Partners
15.3.2.3. Less Likely Partners
15.3.3. Opportunities in Asia-Pacific and Rest of the World
15.3.3.1. Most Likely Partners
15.3.3.2. Likely Partners
15.3.3.3. Less Likely Partners
16. MARKET FORECAST
16.1. Chapter Overview
16.2. Forecast Methodology and Key Assumptions
16.3. Overall BBB Penetration Technologies Market, 2020-2030
16.3.1. BBB Penetration Technologies Market: Contribution from Upfront Payments, 2020-2030
16.3.2. BBB Penetration Technologies Contribution from Milestone Payments, 2020-2030
16.4. Overall BBB Penetrating Drugs Market, 2020-2030
16.4.1. BBB Penetrating Drugs Market: Distribution by Type of Molecule
16.4.1.1. BBB Penetrating Drugs Market for Small Molecules, 2020-2030
16.4.1.2. BBB Penetrating Drugs Market for Biologics, 2020-2030
16.4.2. BBB Penetrating Drugs Market: Distribution by Target Disease Indication
16.4.2.1. BBB Penetrating Drugs Market for Brain Metastases in Breast Cancer, 2020-2030
16.4.2.2. BBB Penetrating Drugs Market for Glioblastoma Multiforme, 2020-2030
16.4.2.3. BBB Penetrating Drugs Market for Hunter Syndrome, 2020-2030
16.4.2.4. BBB Penetrating Drugs Market for Hurler Syndrome, 2020-2030
16.4.3. BBB Penetrating Drugs Market: Distribution by Key Geographical Regions
16.4.3.1. BBB Penetrating Drugs Market in North America, 2020-2030
16.4.3.2. BBB Penetrating Drugs Market in Europe, 2020-2030
16.4.3.3. BBB Penetrating Drugs Market in Asia-Pacific and Rest of the World, 2020-2030
16.4.4. BBB Penetrating Drugs Market: Distribution by Leading Technology Platforms
16.4.5. BBB Penetrating Drugs Market: Distribution by Leading Drug Developers
16.5.6. Drug-wise Sales Forecast
16.5.6.1. 2B3-101 / 2X-111 (2X Oncology)
16.5.6.1.1. Sales Forecast (USD Million)
16.5.6.1.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.1.3. Net Present Value (USD Million)
16.5.6.1.4. Value Creation Analysis
16.5.6.2. AGT-181 (ArmaGen)
16.5.6.2.1. Sales Forecast (USD Million)
16.5.6.2.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.2.3. Net Present Value (USD Million)
16.5.6.2.4. Value Creation Analysis
16.5.6.3. AGT-182 (ArmaGen)
16.5.6.3.1. Sales Forecast (USD Million)
16.5.6.3.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.3.3. Net Present Value (USD Million)
16.5.6.3.4. Value Creation Analysis
16.5.6.4. ANG1005 (Angiochem)
16.5.6.4.1. Sales Forecast (USD Million)
16.5.6.4.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.4.3. Net Present Value (USD Million)
16.5.6.4.4. Value Creation Analysis
16.5.6.5. JR-141 (JCR Pharmaceuticals)
16.5.6.5.1. Sales Forecast (USD Million)
16.5.6.5.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.5.3. Net Present Value (USD Million)
16.5.6.5.4. Value Creation Analysis
17. CONCLUSION
17.1. Chapter Overview
17.2. Key Takeaways
18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Innovative California Biosciences International (ICBI)
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Ram Bhatt, Chief Executive Officer, Chairman and Founder
18.3. Ossianix
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Frank S Walsh, Chief Executive Officer and Founder
18.4. 2-BBB
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Pieter Gaillard, Chief Executive Officer and Co-Founder
18.5. ArmaGen
18.5.1. Company Snapshot
18.5.2. Interview Transcript: Mathias Schmidt, Chief Executive Officer
18.6. biOasis Technologies
18.6.1. Company Snapshot
18.6.2. Interview Transcript: Rob Hutchison, Chief Executive Officer
18.7. Cyclenium Pharma
18.7.1. Company Snapshot
18.7.2. Interview Transcript: Mark L Peterson, Chief Operating Officer
18.8. Sagetis Biotech
18.8.1. Company Snapshot
18.8.2. Interview Transcript: Xavier Rivero, Chief Operating Officer
18.9. CarThera
18.9.1. Company Snapshot
18.9.2. Interview Transcript: Carole Desseaux, Head of Clinical Affairs
18.10. Vect-Horus
18.10.1. Company Snapshot
18.10.2. Interview Transcript: Jamal Temsamani, Head of Drug Development
18.11. Wyss Institute, Harvard University
18.11.1. Organization Snapshot
18.11.2. Interview Transcript: Kevin Kit Parker, Professor
19. APPENDIX I: TABULATED DATA
20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
![She’s 3, but I’m [over 18].](/images/246277_mediumres.jpg)
No comments yet... Be the first to leave a reply! Login here